ERBB2 and breast carcinoma: These cell lines were also selected based on the two difficult-to-treat breast cancers they represent; breast cancer resistant to HER2 therapy for JIMT-1 cells and triple negative breast cancer for MDA-MB-468 (Tanner et al., 2004; Chavez et al., 2010).